

TABLE OF CONTENTS

March 29, 2010

No. 2182

BUSINESS

- 1 Olmesartan, Prasugrel to Drive Sales of Daiichi Sankyo to ¥1,150 Bil. in FY2012
 - Invoice Prices to Be Set at High Levels to Continue to Obtain Premium
 - Aiming at ¥50 Bil. Sales with Rezaltas
- 3 Astellas to Continue to Directly Address OSI's Stockholders
- 3 Erbitux to Be Approved for Use in 1st-Line Therapy
- 4 Bayer to Enhance Links between Diagnostic Imaging, Oncology BU
 - Accelerating Development of PET Tracers Using Molecular Imaging Technology
- 5 GLs Drafted by JPMA for Increased Disclosure on Funds Provided to Med Inst.
- 5 **BUSINESS NEWS IN BRIEF**
 - Eisai Breaks Ground for New Pilot Plant for Biologics
 - Febuxostat Launched in Europe: Teijin
 - NBI Posts Large Fall in Profits Despite 2.4% Increase in Sales
 - Quintiles Relocates Its Global Central Lab in Japan to Tokyo
 - CMIC Ties Up with Biomedical Systems for Image Analysis
 - Toho to Acquire 2 More Dispensing Pharmacy Chains

GENERICS

- 8 Gifu Pref. Orders Taiyo Yakuhi's Takayama Plant to Stop Operation
 - Four Recalls Since February 2009
 - JGA May Consider Expelling Taiyo
 - JGA to Create Ethics Committee
 - JPA Criticizes Taiyo
- 9 Towa to Increase Its Number of MRs to 450
- 10 **GENERICS NEWS IN BRIEF**
 - Value-Based Generics Use Rate of 6.6% Reported by *Kyokai Kenpo*
 - Takata Seiyaku Takes Over 5 Shionogi Brands

REGULATORY

- 10 PMDA to Review Applications for Priority Products within 10 Months
 - PMDA to Strengthen Review System to Handle Extraordinary Applications
 - PMDA Fails to Achieve Its Target Number of Staff Members
 - PMDA to Directly Follow Up ADR Reports from Med. Institutions
- 12 Pharmacists Should Provide More Personalized Medication Guidance: Mr Isobe
 - New Generic Substitution Rule Provides New Opportunity to Pharmacists
- 12 Takeda Withdraws MAA for Actos + Metformin Once-Daily Combination
- 13 Chugai Applies for Combination of Herceptin, Xeloda for Gastric Cancer in Japan

REGULATORY NEWS IN BRIEF

- Actemra Applied for Additional Indication in the US
- Hizentra for PI Approved by FDA: CSL Behring
- NDA for Lurasidone for Schizophrenia Accepted by FDA: DSP
- NDA for Bendamustine Submitted in Taiwan: SymBio
- Dry AMD Treatment ACU-4429 Receives Fast-Track Designation from the FDA: Otsuka, Acucela
- 15 **Commentary**
 - Drug Companies Have No Time to Lose under New Pricing System

R&D

- 16 Treatment of AD Shows Shift from Symptomatic Treatment to Causal Therapy
- 16 Kyowa Kirin Completes New Plant for Investigational Antibodies
- 17 **R&D NEWS IN BRIEF**
 - Cabazitaxel Increases OS in Advanced Hormone-Refractory Prostate Cancer
 - Sutent Fails to Meet Primary Endpoint in PIII for Advanced Breast Cancer
 - Ghrelin Attracts Attention at Protein Mall Kansai

MEDICAL FACILITIES & NURSING CARE

- 18 74th JCS Annual Scientific Meeting
 - Livalo, Lipitor, Crestor Show Comparable Efficacy, Safety
 - ARB + CCB Effective in Patients with Poor Responses to ARB Alone
 - Candesartan, Amlodipine Exert Similar Inhibitory Effects on PAF
 - Coniel as Effective as Tenormin for Secondary Prevention of IHD
 - Over 1,000 Patients Enrolled for Study on Olmetec's Preventive Effects on CV Events
- 20 Discussions Started on Vaccination Act Amendment
 - Bill Presented to Diet to Amend Preventive Vaccination Act
- 20 Osaka Pref. Demands That *Koroshō* Accept Return of Flu Vaccines
- 22 Sapporo City to Subsidize Hib Vaccines from FY2010
- 21 **OPINION**
 - In the Blink of an Eye Philip Carrigan
- 22 **Survey**
 - Only 12% of Free Coupons for Cervical Cancer Checkups Used
- 23 **TOPICS**
 - No Serious Concern about Domestic Flu Vaccines
 - European Counterfeit Market Worth ¥1.26 Tril.: Pfizer UK